A, Intra-arterial retinal precipitates were noticed 8.5 minutes into the treatment, affecting all 4 quadrants. B, Following abortion of treatment, reperfusion proceeded centrifugally in a pulsatile manner. C, The posterior pole was reperfused within the first 90 seconds. D, Full reperfusion of the posterior pole and peripheral retina was noticed clinically 9.5 minutes later.
Fundus photographs of the left eye prior to the first intra-arterial treatment (A) and during the third treatment (B). Note the presence of retinal pigment epithelial clumping inferonasally from the optic nerve (B), in an area not previously affected by the tumor. Also, note the presence of intraretinal perfusion gaps in the temporal aspect of the macula. These precipitates were noticed 20 minutes into the infusion and persisted for a total of 9 minutes. B, The photograph was taken 4.5 minutes into the ischemic episode. Observe the dramatic response of the juxtapapillary tumor to superselective intraophthalmic artery chemotherapy.
Superstein R, Lederer D, Dubois J, Hamel P, Carret A, Callejo S. Retinal Vascular Precipitates During Administration of Melphalan Into the Ophthalmic Artery. JAMA Ophthalmol. 2013;131(7):963-965. doi:10.1001/jamaophthalmol.2013.1469
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
We describe the real-time ophthalmic findings during 3 consecutive bilateral superselective intraophthalmic artery chemotherapy treatments in a 5-month-old baby with retinoblastoma.
After obtaining informed consent, 3 bilateral superselective intraophthalmic artery chemotherapy treatments were performed 1 month apart, following a previously described protocol.1 Each infusion consisted of 2.5 mg of melphalan in 30 mL of saline at a rate of 1 mL/min for 30 minutes per eye. A RetCam 1300 lens (Clarity Medical Systems) was used to take serial fundus photographs and videos. The frequency of the imaging was adjusted according to the findings. Care was taken to avoid applying pressure to the eye.
Results of the first treatment were reported in detail elsewhere.1 In the right eye, signs of widespread chorioretinal ischemia including pulsatile pallor of the optic nerve, sectoral choroidal blanching, retinal arterial thinning, and intra-arterial retinal precipitates (IARPs) were noticed 16 minutes into the infusion. The infusion was immediately aborted and the IARPs persisted for 4.5 minutes. In the left eye, pulsatile pallor of the optic nerve, sectoral choroidal blanching, and marked retinal arterial thinning followed by loss of the blood column along the arterial and venous tree were intermittently recorded during the infusion. Immediate revascularization was noticed following temporary interruption of the infusion. No IARPs were detected. Treatment was completed.
In the right eye, IARPs were noticed 8.5 minutes into the treatment. The infusion was immediately withheld. The IARPs persisted for 9.5 minutes. When clinical chorioretinal reperfusion was detected, the treatment was reinstituted and completed uneventfully (Figure 1). In the left eye, findings were similar to those of the first treatment.
In the right eye, IARPs were noticed 28 minutes into the treatment. The treatment was aborted. The IARPs persisted for 11 minutes. In the left eye, the first episode of IARPs was recorded 20 minutes into the infusion and lasted 9 minutes. When complete chorioretinal reperfusion was clinically noticed, the infusion was continued (Figure 2, , and ). A second ischemic episode with IARPs was recorded immediately after reinstitution of treatment, lasting 7 minutes. Treatment was aborted.
Two months following completion of the treatments, the retinal and choroidal circulation appeared clinically normal. Bilateral electroretinograms were recorded as normal. The tumors were controlled.
Vaso-occlusive disease has been described following superselective intraophthalmic artery chemotherapy as a potentially sight-threatening complication.2- 4 The earliest reported changes consist of ophthalmic and retinal artery occlusions at 1 month following treatment.2 Choroidal vascular atrophy was reported several months later.2 We hypothesize that our intraprocedural vaso-occlusive findings are the cause of vaso-occlusive disease reported by others as late findings. Real-time observation combined with titration of chemotherapy administration may prevent some of these late vaso-occlusive complications.
We hypothesize that these ischemic events would have increased in duration had the infusion been allowed to continue. The IARPs persisted in the right eye and increased in duration with each successive treatment despite immediate withholding of treatment, administration of nitroglycerine, and/or removal of the catheter from the ostium of the ophthalmic artery (Table). In the left eye, the pattern of ischemia changed, from transient ischemic episodes to the presence of IARPs.
Despite our titrated treatment, we had late finding of mild retinal pigment epithelial clumping with normal retinal vasculature and a normal electroretinogram at 2 months’ follow-up (Figure 2). Further studies are needed to elucidate the maximal ischemia that the choroid can tolerate and the role of electroretinography in monitoring these patients.
Until more information becomes available, we are proposing real-time examinations during the infusion with the goal of decreasing the duration of an acute ischemic event.
Corresponding Author: Sonia Callejo, MD, PhD, Department of Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, 3175 Cote-Sainte-Catherine, Montreal, QC H3T 1C5, Canada (email@example.com)
Author Contributions:Study concept and design: Superstein, Dubois, Hamel, Callejo.
Acquisition of data: Superstein, Hamel, Callejo.
Analysis and interpretation of data: Superstein, Lederer, Dubois, Carret, Callejo.
Drafting of the manuscript: Superstein, Lederer, Carret, Callejo.
Critical revision of the manuscript for important intellectual content: Superstein, Lederer, Dubois, Hamel, Callejo.
Administrative, technical, and material support: Superstein, Lederer, Carret, Callejo.
Study supervision: Superstein, Lederer, Callejo.
Conflict of Interest Disclosures: None reported.